Boston Scientific Corporation (NYSE:BSX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average rating of “Moderate Buy” from the thirty-one analysts that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $71.4615.

A number of research analysts recently weighed in on the stock. Oppenheimer reduced their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Royal Bank Of Canada dropped their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Mizuho reduced their price target on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th.

Boston Scientific Price Performance

NYSE BSX opened at $43.00 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a market cap of $62.31 billion, a PE ratio of 17.41, a price-to-earnings-growth ratio of 1.00 and a beta of 0.57. Boston Scientific has a 52 week low of $42.20 and a 52 week high of $105.65. The firm’s 50-day simple moving average is $47.00 and its two-hundred day simple moving average is $54.66.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific will post 3.29 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward Ludwig bought 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the company. Kelleher Financial Advisors purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $25,000. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific during the fourth quarter worth about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new position in Boston Scientific during the first quarter worth about $28,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.